Pollard |
AAML1031 |
31 |
Sorafenib for HAR FLT3/ITD+
patients during chemo and 1 yr of maintenance (post-HCT if donor
available). Sorafenib exposed patients had improved EFS, DFS and relapse
rates. |
AAML1831 – Test gilteritinib, a second generation TKI, that
may be less toxic than sorafenib. |
Davies |
AAML05P1 |
28 |
Prospective study of KIR
typing of unrelated donors prior to donor selection for patients with
AML. No difference in OS, DFS or RR between KIR matched and mismatched.
Acute GVHD rates were lower in the mismatched group. |
PTCTC ONC1401
trial – testing whether KIR mismatches are beneficial with
haploidentical donors |
Reddy |
ACNS0333 |
24 |
Intensified treatment for CNS
AT/RT patients improved 4 yr EFS from 6% to 35%. |
Planned ACNS2232 –
add tazemetostat to ACNS0333 schema to decrease relapse. |
Park |
ANBL0532 |
21 |
Randomized 355 HR NB to 1 (CEM)
vs 2 (Thio/Cy then dose reduced CEM) HCT. Tandem recipients had improved
3 yr EFS 62% vs 48%. |
ANBL1531 – testing whether
131I-MIBG treatment during induction improves
EFS. |
Andolina |
AYA |
36 |
Retrospective analysis of GVHD,
relapse, and survival in 188 pts transplanted on 3 COG protocols for
acute leukemia (ASCT0431, AAML0531, AAML1031). Compared rates of acute
and chronic GVHD, relapse and survival based on younger child (ages
2-12) vs AYA (13-21). AYA were more likely to experience grade II-IV
acute GVHD compared to younger children (56% vs 32%, p=0.006) and less
likely to relapse (20% vs 35%, p=0.032). No difference by age for
chronic GVHD (26% vs 20%, p=0.72), EFS (43% vs 52%, p=0.18) or OS
(49% vs 52%, p=0.56). |
These results formed the basis of the age
stratification in the current ASCT2031 study. |
Schofield |
|
58 |
Joint Cellular Therapy and
Behavioral Sciences task force developed evidence based guidelines for
monitoring neurocognitive outcomes following cellular therapy
treatments. |
Guidelines inform COG CT trial design. |